Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2025)
Historic Interest Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.8 million.
- Aquestive Therapeutics' Interest Expenses fell 3.6% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 475.7%. This contributed to the annual value of $11.1 million for FY2024, which is 7550.89% up from last year.
- As of Q3 2025, Aquestive Therapeutics' Interest Expenses stood at $2.8 million, which was down 3.6% from $2.8 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Interest Expenses ranged from a high of $2.8 million in Q3 2021 and a low of $1.3 million during Q3 2023
- Over the past 5 years, Aquestive Therapeutics' median Interest Expenses value was $2.8 million (recorded in 2021), while the average stood at $2.2 million.
- Its Interest Expenses has fluctuated over the past 5 years, first crashed by 4139.8% in 2022, then surged by 12133.76% in 2024.
- Aquestive Therapeutics' Interest Expenses (Quarter) stood at $1.7 million in 2021, then fell by 5.39% to $1.6 million in 2022, then skyrocketed by 37.76% to $2.3 million in 2023, then grew by 22.26% to $2.8 million in 2024, then changed by 0.0% to $2.8 million in 2025.
- Its last three reported values are $2.8 million in Q3 2025, $2.8 million for Q2 2025, and $2.8 million during Q1 2025.